Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02077010 · ClinicalTrials.gov registry record · Phase 1
Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population
A Phase 1 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02077010 is a Phase 1 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT02077010, a Phase 1 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Patients with end stage heart failure have significant symptoms (including fatigue and shortness of breath) which prevent them from being able to perform most activities of daily living. Milrinone is one of the inotropic medications that has been studied and used in the treatment of end stage heart failure. End stage heart failure patients awaiting a heart transplantation often have to be maintained on IV milrinone 24 hours a day through a chronic IV line. Two problems arise with this therapy. First, the IV line itself creates an opportunity for infection and blood clots, in addition to interfering with patient's quality of life. Second, patients may be exposed to higher levels of milrinone when given IV than are necessary for maintaining their heart's function. By doing this study the investigators hope to learn if a new way of giving HF patients milrinone can lower the levels of plasma milrinone which may lessen the chance of medication side effects, while still preserving the beneficial effects of milrinone. Additionally if the inhaled route of administration is effective patients may not need to have invasive IV lines to administer the medication (currently standard practice) which can cause other unwanted side effects.
Interventions
- DRUG Inhaled nebulized milrinone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2023-01-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02077010
The ClinicalTrials.gov registry entry for NCT02077010 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inhaled nebulized milrinone is the first listed.
NCT02077010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02077010 about?
NCT02077010 is a clinical study titled "Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population". Patients with end stage heart failure have significant symptoms (including fatigue and shortness of breath) which prevent them from being able to perform most activities of daily living. Milrinone is one of the inotropic medications that has been studied and used in the treatment of end stage heart ...
What is the current status of trial NCT02077010?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2020-06-15. Estimated completion is 2023-01-24.
What interventions are being tested in trial NCT02077010?
The interventions under investigation include: Inhaled nebulized milrinone (DRUG).
Who is sponsoring clinical trial NCT02077010?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.